Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter ...
The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback